The Role of Ectopic Fat and Heart Attack Risk in HIV (BHIVA)

February 17, 2026 updated by: University of Liverpool

The Association of Ectopic Fat and Cardiovascular Disease in People Living With HIV and General Populations: A Cross Sectional Analysis

This study is designed to investigate differences between people living with HIV (PLWHIV) and general populations on how the body utilises and stores energy. This study uses magnetic resonance imaging (MRI) to measure fat around the body organs including the heart and liver. The fat around body organs, also known as visceral fat, is known to be associated with metabolic syndrome and a risk factor for developing heart attacks and strokes.

MRI scans are used frequently in hospitals to diagnose a range of conditions. These scans use radio waves to measure protons in body tissues. The machines can reconstruct tissues using complex algorithms to form composite images of body structures. MRI scans do not use ionising radiation and there is no risk to undertaking an MRI in terms of radiation.

We often use MRI scans to assess the hearts' structure and function. In addition, we can use specific MRI sequences to assess the integrity of heart muscle. Heart MRI is often considered the gold standard imaging technique to assess the heart and heart muscle disease. This sub-study will use multiple MRI sequences to assess the heart and the liver. We are aiming to investigate any changes in heart and liver fat. In addition, we will assess any changes in fat levels within the heart muscle cells whilst also assessing for any change in the way the heart is functioning.

PLWHIV have roughly double the risk of heart attacks compared to general populations. Previous studies have demonstrated that this increased risk may arise from the way in which fat is stored and metabolised in the body. We hope this study will give insight into why HIV-positive individuals have increased risks of heart attacks and how reducing visceral fat may reduce risk. It may lead to further medicines or treatment strategies to reduce the risk of heart attacks in HIV-positive individuals.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

PLWHIV have an increased risk of developing cardiovascular disease compared to risk matched HIV-negative patients. CVD is a leading cause of morbidity and mortality in PLWHIV and increasing burden on healthcare systems. One model has suggested that the median age of PLWHIV will increase from 43.9 years in 2010 to 56.6 years in 2030 with 78% being diagnosed with CVD. Traditional risk predication tools have been demonstrated to perform poorly in this patient cohort.

This increased risk may be driven by several factors. Viral related mechanisms, ART, and increased prevalence of traditional risk factors (smoking, poor diet, sedentary lifestyle) act in a synergistic fashion to enhance the cardiovascular risk seen in HIV-positive patients. Recent data has focused on the role of energy metabolism as a mechanistic driver for this excess risk. Accessory proteins from the virus and certain antiretroviral agents are known to induce adipocyte dysfunction through reduction of pre-adipocyte differentiation, muted insulin-sensitivity, increased lipolysis, and mitochondrial stress. The net effect of these changes promotes 'central' storage of energy (fatty acids) in VAT and ectopic fat, of which the principal sites are the hepatic parenchyma (NAFLD) and EAT.

Both NAFLD and EAT are increasingly recognised as risk factors for CVD in both PLWHIV and HIV-negative groups. PLWHIV are 25% more likely to develop NAFLD at normal body weights compared to HIV-negative groups. Our work, and others, have demonstrated a significant association of NAFLD in PLWHIV but less so in HIV-negative groups . EAT volume has again been demonstrated to be associated with CVD in general populations. EAT shares a common microcirculation with the epicardial coronary arteries and exerts influence on vascular function through adipokine secretion, buffering of fatty acids, and secretion of inflammatory cytokines. The close anatomical relationship between EAT and the epicardial coronary arteries may indicate a novel substrate for atherogenesis in the context of EAT dysfunction. Again, our work has demonstrated a strongly significant association between EAT volume and incident CVD.

Emerging imaging studies are utilising cardiac MRS to measure intramyocardial metabolites and associations with health and disease. Cardiac MRS provides the ability to co-localise cardiac anatomy, tissue composition and energetic performance in vivo giving the ability to study the pathophysiology and cell biology of metabolic syndrome, glucose metabolism and ectopic fat deposition. Phosphorus MRS allows quantification of calculation of phosphocreatine to ATP ratio (PCr/ATP) which is a marker of myocardial energetic state. Using phosphorus MR spectroscopy myocardial energetic substrate compromise has been found in diabetic cardiomyopathy. It has also been used to study the effects of SGLT2 inhibitors on cardiac energy substrate utilisation. Proton MR spectroscopy allows quantification of intracellular triglyceride which allows further assessment of the metabolic status of cardiac tissue. Previous work has demonstrated increased cardiac steatosis, on cardiac MR spectroscopy, in HIV-positive patients compared to HIV-negative patients . HIV-positive women increased cardiac steatosis was associated with evidence of cardiac diastolic dysfunction. The use of MRS (proton and 31-P) to study the impact of therapeutic interventions on ectopic fat has never been studied in HIV.

Cardiovascular CT is an important imaging modality with widespread clinical and research utility. It has the ability to inform on multiple metrics of CVD including total plaque volume, non-calcified plaque volume, calcium score (Agatston score), plaque morphology and stenosis grading. The use of these measures as surrogates for CVD risk has been used extensively over the last two decades. This imaging modality is of critical importance to HIV / CVD research as trials powered for CVD outcomes are not feasible.

Recent advances in biomarkers related to adipocyte health and NAFLD are of significant interest in PLWHIV. Fetuin A has been demonstrated to be associated with vascular calcification in those with obesity, NAFLD and metabolic syndrome. Adiponectin is another biomarker which is closely associated with adipocyte health and insulin resistance.

Multiparametric measures of ectopic fat (MRS, Fiborscan), cardiac structure and function (CMR), adipocyte health biomarkers (using tissue, serum and plasma) in association with CVD risk have not been studied in the same setting. We have designed this detailed cross-sectional analysis comparing PLWHIV to risk-matched general groups to inform on the role of ectopic fat in CVD in PLWHIV. This is of critical importance to gain mechanistic insight into the excess CVD risk seen in PLWHIV whilst also providing potential therapeutic targets for emerging drugs.

The increasing morbidity and mortality that CVD represents in this ageing group is of pressing concern. It represents an emerging health economic challenge for already stretched Western healthcare systems. Understanding HIV-specific mechanistic drivers of the excess CVD risk and potential therapeutic targets is therefore highly desirable. Our data and others suggest an important role for altered energy metabolism causing increased ectopic fat deposition. The development and realisation of specific therapeutics, that reduce ectopic and visceral fat, is of great interest for risk reduction strategies specifically for PLWHIV. Further understanding of the link between ectopic fat and CVD is required prior to embarking on randomised control trials for these agents. We have designed a comprehensive cross-sectional analysis investigating the associations of ectopic and visceral fat (multiple measures), intramyocardial lipid (cardiac MR spectroscopy), cardiac structure and function (CMR), biomarkers specific to energy metabolism (serum/plasma biomarkers), adipocyte health (tissue) with incident CVD (cardiovascular CT) in HIV-positive and HIV-negative / general population individuals.

The use of multiple measures of ectopic fat, including biomarkers for adipocyte health in serum and tissue, with incident CVD has not been done before. We anticipate that the data generated from this study will inform power calculations for future randomised control studies investigating the use of therapeutics on ectopic fat reduction in PLWHIV.

We have designed a cross sectional study to assess the relationship between EAT volume and CVD risk in PLWHIV and general populations. Participants will be recruited from the regional HIV service hosted by LUHFT. HIV-negative / general population participants will be recruited from those undergoing CT Coronary Angiography.

The study will involve 50 HIV-positive subjects and 50 general subjects. HIV-positive subjects will be recruited from follow up clinics and will have stable HIV disease (VL<40 copies/ml) and CD4 counts >200cells/mm3 for a minimum of 1 year. All subjects will be required to read the patient information leaflet and sign the consent form before enrolment to the study. Participants will be stratified into low (n=10), moderate (n=20) and high (n=20) risk according to traditional scoring methods. We will also include within these numbers 20 subjects with documented weight gain on INSTI regimes.

Study Type

Observational

Enrollment (Estimated)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United Kingdom
      • Liverpool, United Kingdom
        • Recruiting
        • Royal Liverpool University Hospital
        • Contact:
        • Principal Investigator:
          • Thomas Heseltine

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Probability Sample

Study Population

50 participants from HIV clinic 50 participants from general population (patients undergoing CT Coronary Angiography for investigation of chest pain)

Description

Inclusion Criteria:

  • • >40 years

    • HIV-positive
    • Stable ART for >6 months with two VL <40 copies/ml based on local testing protocols
    • CD4 count >200cells/mm3 for >2 years from recruitment Inclusion Criteria (all)
    • Understand the study procedures, able to comply with study procedures and voluntarily agree to participate by giving informed written consent

Exclusion Criteria:

  • Subjects unable to comply with the study protocol
  • History of severe renal impairment (eGFR <30ml/min)
  • History of severe hepatic impairment (Child Pugh Score >9)
  • Active hepatitis B or hepatitis C
  • Any active illness, which in the opinion of the investigator precludes participation in the study.
  • History of cancer
  • Active illicit intravenous drug use
  • Investigators may decide the subject cannot proceed if there are any relevant other abnormal results in screening assessments
  • History or current GLP-1 agonist use
  • For female subjects: pregnancy or breast feeding at screening.
  • Subjects currently taking: Atypical antipsychotics, omega 3 supplements, Telmisartan/Irbesartan, Thiazolidinediones or regular NSAID use.
  • Familial hypercholesterolaemia

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
General population
People living with HIV
Other: Non-interventional
Non-interventional

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Epicardial adipose tissue volume
Time Frame: Through study completion, an average of 1 year
Epicardial adipose tissue volume measured by cardiac MRI (mm3). Measurment of fat around the heart
Through study completion, an average of 1 year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Intramyocardial triglyceride
Time Frame: through study completion, an average of 1 year
MR spectroscopy. MEasurement of concentration of intramyocardial lipid content
through study completion, an average of 1 year
Liver fat percentage
Time Frame: through study completion, an average of 1 year
As described my MRI spectroscopy protocol. Measurement of fat content of liver cells
through study completion, an average of 1 year
LV ejection fraction
Time Frame: through study completion, an average of 1 year
As defined on cardiac MRI (%). Cardiac performance
through study completion, an average of 1 year
Global native myocardial T1 times
Time Frame: through study completion, an average of 1 year
As defined on cardiac MRI (ms). Measure of myocardial fibrosis
through study completion, an average of 1 year
Lipids
Time Frame: through study completion, an average of 1 year
total cholesterol (mmol/L), high density cholesterol (mmol/L), low density cholesterol (mmol/L), triglyceride (mmol/L)
through study completion, an average of 1 year
LV strain on MRI
Time Frame: through study completion, an average of 1 year
As defined on cardiac MRI (%). Parameter for myocardial performance
through study completion, an average of 1 year
HBA1c
Time Frame: through study completion, an average of 1 year
Biomarkers for insulin metabolic health(mmol/L)
through study completion, an average of 1 year
Adiponectin
Time Frame: through study completion, an average of 1 year
Biomarkers for insulin metabolic health (ug/ml),
through study completion, an average of 1 year
Insulin
Time Frame: through study completion, an average of 1 year
Biomarkers for insulin metabolic health(uU/ml)
through study completion, an average of 1 year
Health status
Time Frame: through study completion, an average of 1 year
Follow up will be remotely completed to record new diagnoses from electronic records for 5years.
through study completion, an average of 1 year
CAP score
Time Frame: through study completion, an average of 1 year
Fibroscan (dB/m). Measurement of liver fibrosis / fat
through study completion, an average of 1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Liverpool

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 1, 2024

Primary Completion (Estimated)

June 30, 2027

Study Completion (Estimated)

June 30, 2027

Study Registration Dates

First Submitted

January 30, 2024

First Submitted That Met QC Criteria

January 17, 2025

First Posted (Actual)

January 20, 2025

Study Record Updates

Last Update Posted (Actual)

February 19, 2026

Last Update Submitted That Met QC Criteria

February 17, 2026

Last Verified

February 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • UOL001832

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

IPD Plan Description

We will evaluate upon reasonable request to share study data (anonymised)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hiv

Clinical Trials on Non-interventional

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Arab Emirates

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe